Search results
SESEN BIO, INC. (SESN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Zacks via Yahoo Finance· 2 years agoAfter losing some value lately, a hammer chart pattern has been formed for SESEN BIO, INC. (SESN),...
SESEN BIO, INC. (SESN) Stock Moves -0.43%: What You Should Know
Zacks via Yahoo Finance· 2 years agoSESEN BIO, INC. (SESN) closed at $0.39 in the latest trading session, marking a -0.43% move from the...
Sesen (SESN) Halts Bladder Cancer Drug Development, Stock Down
Zacks via Yahoo Finance· 2 years agoSesen Bio (SESN) decides to pause the development of Vicineum in the United States. It also ended...
Sesen Bio (SESN) to Report Q3 Earnings: What's in the Cards?
Zacks via Yahoo Finance· 2 years agoIn the third quarter of 2022 results,we expect investors to focus onSesen Bio’s SESN near-term...
Sesen Bio (NASDAQ:SESN) investors are sitting on a loss of 37% if they invested three years ago
Simply Wall St. via Yahoo Finance· 1 year agoMany investors define successful investing as beating the market average over the long term. But in...
What's in the Cards for Sesen Bio's (SESN) Q2 Earnings?
Zacks via Yahoo Finance· 2 years agoSesen Bio's (SESN) Q2 performance is likely to reflect cost savings from the company's restructuring...
SESEN BIO, INC. (SESN) Upgraded to Buy: What Does It Mean for the Stock?
Zacks via Yahoo Finance· 2 years agoSESEN BIO, INC. (SESN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about...
Novartis, Moderna Partner Agrees To Merge With Beleaguered Sesen Bio
Benzinga via Yahoo Finance· 2 years agoSesen Bio Inc (NASDAQ: SESN) and privately held Carisma Therapeutics Inc have entered into a merger...
Sesen Bio Pauses Clinical Development Of Its Lead Bladder Cancer Candidate In US
Benzinga via Yahoo Finance· 2 years agoBased on a thorough reassessment Sesen Bio Inc (NASDAQ: SESN) has decided to voluntarily pause...
Epizyme (EPZM) Q2 Earnings Beat Estimates, Revenues Up Y/Y
Zacks via Yahoo Finance· 2 years agoEpizyme, Inc. EPZM incurred a loss of 21 cents per share in second-quarter 2022, narrower than the...